AR097464A1 - Anticuerpos anti-csf-1r (factor estimulante de colonias 1) - Google Patents
Anticuerpos anti-csf-1r (factor estimulante de colonias 1)Info
- Publication number
- AR097464A1 AR097464A1 ARP140103206A ARP140103206A AR097464A1 AR 097464 A1 AR097464 A1 AR 097464A1 AR P140103206 A ARP140103206 A AR P140103206A AR P140103206 A ARP140103206 A AR P140103206A AR 097464 A1 AR097464 A1 AR 097464A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- cdr
- antibody
- sec
- sequence given
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
Reivindicación 1: Un anticuerpo anti-CSF-1R que comprende una cadena pesada, caracterizado porque el dominio variable de la cadena pesada comprende al menos una de las siguientes: una CDR que tiene la secuencia dada en la ID. DE SEC. Nº 4 para CDR-H1, una CDR que tiene la secuencia dada en la ID. DE SEC. Nº 5 para CDR-H2 y una CDR que tiene la secuencia dada en la ID. DE SEC. Nº 6 para CDR-H3. Reivindicación 19: Una secuencia de ADN aislado que codifica una o más cadenas pesadas y/o livianas de un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 18. Reivindicación 23: Un proceso para la producción del anticuerpo de una cualquiera de las reivindicaciones 1 a 18, que comprende cultivar la célula hospedadora de acuerdo con la reivindicación 22 y asilar el anticuerpo. Reivindicación 24: Una composición farmacéutica que comprende un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 18, en combinación con uno o más excipientes, diluyentes o portadores farmacéuticamente aceptables. Reivindicación 33: El anticuerpo para utilizar de acuerdo- con la reivindicación 27, el uso de acuerdo con la reivindicación 29 o el método de acuerdo con la reivindicación 31, caracterizados porque el cáncer se selecciona del grupo que consiste en cáncer de mama, cáncer de próstata, cáncer de huesos, cáncer colorrectal, leucemia, linfoma, cáncer de piel, cáncer esofágico, cáncer gástrico, cáncer astrocítico, cáncer de endometrio, cáncer cervical, cáncer de vejiga, cáncer renal, cáncer de pulmón, cáncer de hígado, cáncer de tiroides, cáncer de cabeza. y cuello cáncer de páncreas y cáncer de ovario.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1315487.7A GB201315487D0 (en) | 2013-08-30 | 2013-08-30 | Antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
AR097464A1 true AR097464A1 (es) | 2016-03-16 |
Family
ID=49397073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140103206A AR097464A1 (es) | 2013-08-30 | 2014-08-27 | Anticuerpos anti-csf-1r (factor estimulante de colonias 1) |
Country Status (39)
Country | Link |
---|---|
US (2) | US9908939B2 (es) |
EP (3) | EP3549599B1 (es) |
JP (3) | JP6632075B2 (es) |
KR (1) | KR102303130B1 (es) |
CN (2) | CN105658236B (es) |
AR (1) | AR097464A1 (es) |
AU (1) | AU2014314304B2 (es) |
BR (1) | BR112016004324B1 (es) |
CA (1) | CA2922240C (es) |
CL (1) | CL2016000438A1 (es) |
CY (1) | CY1121964T1 (es) |
DK (2) | DK3549599T3 (es) |
EA (1) | EA036255B1 (es) |
ES (2) | ES2733735T3 (es) |
FI (1) | FI3549599T3 (es) |
GB (1) | GB201315487D0 (es) |
HK (1) | HK1220142A1 (es) |
HR (2) | HRP20231264T1 (es) |
HU (2) | HUE064437T2 (es) |
IL (1) | IL244043B (es) |
LT (2) | LT3038643T (es) |
MA (2) | MA38930A1 (es) |
MX (1) | MX2016002166A (es) |
MY (1) | MY172484A (es) |
NZ (1) | NZ717399A (es) |
PE (2) | PE20201067A1 (es) |
PH (1) | PH12016500275B1 (es) |
PL (2) | PL3549599T3 (es) |
PT (2) | PT3038643T (es) |
RS (2) | RS64784B1 (es) |
SG (1) | SG11201601151PA (es) |
SI (2) | SI3549599T1 (es) |
TN (1) | TN2016000067A1 (es) |
TR (1) | TR201909478T4 (es) |
TW (1) | TWI531582B (es) |
UA (1) | UA118354C2 (es) |
UY (1) | UY35718A (es) |
WO (1) | WO2015028455A1 (es) |
ZA (1) | ZA201601437B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
US10316097B2 (en) * | 2015-05-27 | 2019-06-11 | Ucb Biopharma Sprl | Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody |
EP3302552A1 (en) * | 2015-06-02 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
CN109475603B (zh) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | 抗pd-l1抗体 |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
AU2018269039A1 (en) * | 2017-05-19 | 2019-12-19 | Syndax Pharmaceuticals, Inc. | Combination therapies |
GB201803226D0 (en) | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
CN108948198B (zh) * | 2018-07-18 | 2020-09-01 | 博奥信生物技术(南京)有限公司 | 抗人csf-1r单克隆抗体及其应用 |
CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术(南京)有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
CN113301960A (zh) * | 2018-12-13 | 2021-08-24 | 财团法人生物技术开发中心 | 抗人类csf-1r抗体和其用途 |
WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
CN114835811B (zh) * | 2019-12-24 | 2024-03-26 | 宝船生物医药科技(上海)有限公司 | 抗csf1r分子及其用途 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
EP1570267B1 (en) | 2002-12-03 | 2011-10-12 | UCB Pharma, S.A. | Assay for identifying antibody producing cells |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
SI1644412T2 (sl) | 2003-07-01 | 2018-11-30 | Ucb Biopharma Sprl | Modificirani fab fragmenti protiteles |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
JP5718640B2 (ja) * | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトc−fms抗原結合性タンパク質 |
CN101842387B (zh) | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
US8470977B2 (en) * | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
WO2009112245A1 (en) | 2008-03-14 | 2009-09-17 | Transgene S.A. | Antibody against the csf-1 r |
CN105601745B (zh) | 2008-09-26 | 2020-09-08 | Ucb医药有限公司 | 生物产品 |
WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
ES2722300T3 (es) * | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
CN102918060B (zh) * | 2010-03-05 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | 抗人csf-1r抗体及其用途 |
US9221910B2 (en) * | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
SI2566517T1 (sl) * | 2010-05-04 | 2019-01-31 | Five Prime Therapeutics, Inc. | Protitelesa, ki vežejo CSF1R |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
GB201315486D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
-
2013
- 2013-08-30 GB GBGB1315487.7A patent/GB201315487D0/en not_active Ceased
-
2014
- 2014-08-05 TW TW103126815A patent/TWI531582B/zh active
- 2014-08-26 HR HRP20231264TT patent/HRP20231264T1/hr unknown
- 2014-08-26 PT PT14755668T patent/PT3038643T/pt unknown
- 2014-08-26 CN CN201480057403.8A patent/CN105658236B/zh active Active
- 2014-08-26 EP EP19171833.7A patent/EP3549599B1/en active Active
- 2014-08-26 FI FIEP19171833.7T patent/FI3549599T3/fi active
- 2014-08-26 WO PCT/EP2014/068050 patent/WO2015028455A1/en active Application Filing
- 2014-08-26 LT LTEP14755668.2T patent/LT3038643T/lt unknown
- 2014-08-26 HU HUE19171833A patent/HUE064437T2/hu unknown
- 2014-08-26 HU HUE14755668A patent/HUE045672T2/hu unknown
- 2014-08-26 PT PT191718337T patent/PT3549599T/pt unknown
- 2014-08-26 PL PL19171833.7T patent/PL3549599T3/pl unknown
- 2014-08-26 CA CA2922240A patent/CA2922240C/en active Active
- 2014-08-26 EP EP14755668.2A patent/EP3038643B1/en active Active
- 2014-08-26 CN CN202011009068.8A patent/CN112321711A/zh active Pending
- 2014-08-26 MY MYPI2016700624A patent/MY172484A/en unknown
- 2014-08-26 SG SG11201601151PA patent/SG11201601151PA/en unknown
- 2014-08-26 LT LTEP19171833.7T patent/LT3549599T/lt unknown
- 2014-08-26 BR BR112016004324-3A patent/BR112016004324B1/pt active IP Right Grant
- 2014-08-26 DK DK19171833.7T patent/DK3549599T3/da active
- 2014-08-26 MX MX2016002166A patent/MX2016002166A/es active IP Right Grant
- 2014-08-26 UA UAA201601175A patent/UA118354C2/uk unknown
- 2014-08-26 RS RS20230962A patent/RS64784B1/sr unknown
- 2014-08-26 NZ NZ717399A patent/NZ717399A/en unknown
- 2014-08-26 ES ES14755668T patent/ES2733735T3/es active Active
- 2014-08-26 RS RS20190833A patent/RS59019B1/sr unknown
- 2014-08-26 TN TN2016000067A patent/TN2016000067A1/en unknown
- 2014-08-26 DK DK14755668.2T patent/DK3038643T3/da active
- 2014-08-26 PL PL14755668T patent/PL3038643T3/pl unknown
- 2014-08-26 TR TR2019/09478T patent/TR201909478T4/tr unknown
- 2014-08-26 AU AU2014314304A patent/AU2014314304B2/en active Active
- 2014-08-26 MA MA38930A patent/MA38930A1/fr unknown
- 2014-08-26 KR KR1020167007073A patent/KR102303130B1/ko active IP Right Grant
- 2014-08-26 MA MA44922A patent/MA44922B1/fr unknown
- 2014-08-26 JP JP2016537262A patent/JP6632075B2/ja active Active
- 2014-08-26 PE PE2020000532A patent/PE20201067A1/es unknown
- 2014-08-26 SI SI201432048T patent/SI3549599T1/sl unknown
- 2014-08-26 ES ES19171833T patent/ES2965207T3/es active Active
- 2014-08-26 SI SI201431235T patent/SI3038643T1/sl unknown
- 2014-08-26 EP EP23192221.2A patent/EP4282881A3/en active Pending
- 2014-08-26 EA EA201690503A patent/EA036255B1/ru not_active IP Right Cessation
- 2014-08-26 US US14/914,676 patent/US9908939B2/en active Active
- 2014-08-26 PE PE2016000313A patent/PE20160528A1/es unknown
- 2014-08-27 AR ARP140103206A patent/AR097464A1/es unknown
- 2014-08-29 UY UY35718A patent/UY35718A/es not_active Application Discontinuation
-
2016
- 2016-02-09 IL IL244043A patent/IL244043B/en active IP Right Grant
- 2016-02-10 PH PH12016500275A patent/PH12016500275B1/en unknown
- 2016-02-25 CL CL2016000438A patent/CL2016000438A1/es unknown
- 2016-03-02 ZA ZA2016/01437A patent/ZA201601437B/en unknown
- 2016-07-15 HK HK16108335.9A patent/HK1220142A1/zh unknown
-
2018
- 2018-01-30 US US15/883,130 patent/US10421814B2/en active Active
-
2019
- 2019-06-12 HR HRP20191051TT patent/HRP20191051T1/hr unknown
- 2019-07-23 CY CY20191100779T patent/CY1121964T1/el unknown
- 2019-09-13 JP JP2019166697A patent/JP7195237B2/ja active Active
-
2021
- 2021-09-17 JP JP2021152574A patent/JP2022002523A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR097464A1 (es) | Anticuerpos anti-csf-1r (factor estimulante de colonias 1) | |
EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
DOP2021000023A (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
AR102918A1 (es) | Anticuerpos anti-cd79b y métodos de uso | |
RS54627B1 (en) | CANCER EXPRESSION ANTIBODIES THAT EXPLAIN CLAUDINE 6 | |
MX2016017311A (es) | Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas. | |
MX2018002166A (es) | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. | |
AR102554A1 (es) | Receptores quiméricos de antígeno anti-cldn y métodos de uso | |
AR102879A1 (es) | Métodos para el tratamiento de tumores cerebrales | |
RU2018146533A (ru) | Антитела к cd40 и пути их применения | |
NZ628314A (en) | Cd47 antibodies and methods of use thereof | |
MY176822A (en) | Anti-pd-1 antibody and use thereof | |
WO2014012085A3 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
MX2014005728A (es) | Anticuerpos especificos para antigeno de la superficie celular de trofoblasto-2 y sus usos. | |
AR092737A1 (es) | Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf, uso y metodo de tratamiento del cancer | |
MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
MA40612A (fr) | Nouveaux anticorps anti-mfi2 et méthodes d'utilisation | |
MX2019004940A (es) | Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1. | |
MX2017005925A (es) | Metodos de producción de proteínas de cadena doble en bacterias. | |
PH12017500309A1 (en) | Anti-vasa antibodies, and methods of production and use thereof | |
MX2023008887A (es) | Combinaciones farmaceuticas que comprenden un anticuerpo anti-ly75. | |
RU2016148682A (ru) | Антитела против рецептора-3 к эпидермальному ростовому фактору человека (her3), связывающиеся с бета-шпилькой her3 |